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Main drivers of (poly)phenol effects on human
health: metabolite production and/or gut
microbiota-associated metabotypes?
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Despite the high human interindividual variability in response to (poly)phenol consumption, the cause-
and-effect relationship between some dietary (poly)phenols (flavanols and olive oil phenolics) and health
effects (endothelial function and prevention of LDL oxidation, respectively) has been well established.
Most of the variables affecting this interindividual variability have been identified (food matrix, gut micro-
biota, single-nucleotide-polymorphisms, etc.). However, the final drivers for the health effects of (poly)
phenol consumption have not been fully identified. At least partially, these drivers could be (i) the (poly)
phenols ingested that exert their effect in the gastrointestinal tract, (ii) the bioavailable metabolites that
exert their effects systemically and/or (iii) the gut microbial ecology associated with (poly)phenol metab-
olism (i.e., gut microbiota-associated metabotypes). However, statistical associations between health
effects and the occurrence of circulating and/or excreted metabolites, as well as cross-sectional studies
that correlate gut microbial ecologies and health, do not prove a causal role unequivocally. We provide a
critical overview and perspective on the possible main drivers of the effects of (poly)phenols on human
health and suggest possible actions to identify the putative actors responsible for the effects.
1. Introduction
Historically, dietary (poly)phenols, such as flavonoids, evolved
from possible compounds with vitamin-like properties to non-
essential nutrients1 (check the comprehensive and excellent
review on the metabolism and bioactivity of flavonoids from a
historical perspective by Williamson et al.2). Later, (poly)
phenols were considered anti-nutrients with potential
mutagen and carcinogenic activities.3 However, this perception
changed when epidemiological studies showed an inverse
relationship between the consumption of plant foods and
cancer risk,4 and primarily cardiovascular disease (CVD) risk.5
Together with early experimental studies, these observations
endorsed the health-promoting effects observed from the flavo-
noid content of fruits and vegetables, and the most plausible
mechanism of action was attributed to the antioxidant activity
of flavonoids.5–7 In the late 1990s and early 2000s, there was a
massive output of in vitro studies describing the free radical
scavenging capacity of (poly)phenol-rich plant extracts, estab-
lishing a potential health claim based merely on the content
of (poly)phenols in foods.8–11 Later, ADME (absorption, distri-
bution, metabolism, and excretion) studies showed that (poly)
phenols are poorly bioavailable, i.e., the proportion of intact
(poly)phenolic compounds ingested that reach the blood-
stream is low.12–16 Upon absorption, phase-II enzymes exten-
sively metabolise (poly)phenols, yielding conjugated metab-
olites that can show some activity but are much lower than
their food-occurring phenolic precursors.17–20 This evidence
questions the reliability of thousands of in vitro results based
on non-physiological conditions, i.e., the assay of food-occur-
ring (poly)phenols instead of their physiologically relevant
conjugates.21 Unfortunately, this useless approach persists.
To date, a substantial number of human studies and meta-
analyses have discussed the preventive effects of (poly)phenol-
containing foods against cardiometabolic diseases and, to a
lesser extent, against some types of cancer and neurodegenera-
tive diseases.22–33 However, there is controversy and not all the
studies reach conclusive links between (poly)phenols and
health, even for the same outcome, e.g., vascular function, per-
formed by the same research group and assaying the same
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pure flavonoid, e.g. epicatechin.34,35 Overall, most systematic
reviews and meta-analyses on (poly)phenols and health high-
light the finding of some “promising” or “potential” health
effects, but conclude with the same call of caution: “…more
high-quality research is needed…”, “…further well-designed ran-
domised and controlled trials are required…”
A well-established cause-and-effect relationship between
most (poly)phenols consumed and their possible beneficial
effects remains elusive. In this regard, many of their related
health claims have been rejected by the European Food Safety
Agency (EFSA). Indeed, except for a few examples of health
benefits, including protection of low-density lipoprotein chole-
sterol (LDLc) particles from oxidative damage by olive oil phe-
nolics such as hydroxytyrosol,36 and improvement of endo-
thelial function by cocoa flavanols,37 most of the health effects
of dietary (poly)phenols have not been unequivocally proven.
Even in these cases, the final triggering metabolite for the
effects is unknown. Beyond antioxidant activity, many mecha-
nisms for the action of (poly)phenols have been described,
including the modulation of inflammatory mediators, fat
metabolism, and transcription factors,38–40 but the actual
mechanisms behind the effects have not been fully estab-
lished. We do not aim here to review possible determinants
affecting (poly)phenols effects, an issue extensively reviewed in
recent years under the COST Action POSITIVe activities.41–43
However, it is not yet clear whether the effects observed after
polyphenol-rich food consumption are mainly exerted by: (i)
the ingested phenolics, (ii) their phase-II derived metabolites,
(iii) the greater or lesser amount of phenolic-derived metab-
olites produced by the microbiota (metabolite gradient), and/
or (iv) the specific gut microbiota associated with the metab-
olism of (poly)phenols (the so-called gut microbiota
metabotypes).
Therefore, we aim to provide an overview and perspective to
address which player(s), i.e., metabolite production and/or gut
microbiota-associated metabotypes, could be responsible for
the observed health effects in humans upon (poly)phenol
consumption.
2. Interindividual variability in
response to (poly)phenol
consumption: in search of the putative
driver responsible for the effects
It has long been known that the clinical response to drug
administration varies widely between individuals.44 Similarly,
increasing evidence began to appear on interindividual varia-
bility in the metabolism of certain dietary (poly)phenols, such
as isoflavones,45 flavanones,46 tea catechins,47 and ellagitan-
nins,48 among others. In parallel, other studies also began to
throw controversy about the statistical significance of the
observed effects due to the large standard deviations of the
results obtained.22 In this regard, the wide range of (poly)
phenol structures was suggested to be a crucial factor that
impacts their metabolism and could be behind the wide varia-
bility in the effects on biomarkers of CVD risk.49–51 However,
despite dietary (poly)phenols being structurally different,
many share the same multi-target action mechanisms.2
Finally, there is notable interindividual variability in response
to (poly)phenol consumption. Overall, this avoids claiming
that (poly)phenols exert health effects for the entire popu-
lation, which could be behind the rejection by EFSA of many
health claims for (poly)phenols. Instead, the participation of
many specific variables leads us to personalised dietary rec-
ommendations that consider a complex mixture of individuals’
conditions (sex, age, genetic makeup, lifestyle, physiological
status, and gut microbiota) and other aspects (food matrix and
processing, dietary patterns, etc.).41,43,52–57 It seems that not all
of these conditions and aspects necessarily contribute equally.
However, the possible weight of importance for each contribu-
tor is not known.
In the last decade, the two-way interaction between (poly)
phenols and gut microbiota (modulation of the microbiota by
(poly)phenols and metabolism of (poly)phenols by the micro-
biota) has attracted attention as a new piece in the puzzle of
(poly)phenols and health.43,53,58,59 In the search for the main
actor(s) involved in the final (poly)phenol health effects,
growing evidence has identified their derived microbial metab-
olites as a possible connection to establishing the bioactivity
of (poly)phenols. However, the two-way interaction between
the gut microbiota and dietary (poly)phenols is also the main
driver of the interindividual variation detected.43,59,60 In
addition to the possible bioactivity exerted by the ingested
(poly)phenols and/or their derived microbial derivatives, each
individual’s gut microbiota, including that involved in (poly)
phenol metabolism, is also relevant to explain the final effects.
For example, the daidzein-derived metabolite equol was
suggested as being more bioactive than its daidzein precursor
and seemed to be predominant in some individuals capable of
producing equol (i.e., “equol producers”).61 Similarly, the pres-
ence of urolithins in the bloodstream was initially claimed as a
plausible explanation behind the effects observed after con-
sumption of foods containing the non-bioavailable urolithin
precursors ellagitannins.48,62 However, not all individuals
produce the same urolithins, nor harbour the same associated
gut microbiota.43,63
While the determinants affecting the individuals’ response
to (poly)phenol consumption have been comprehensively
identified,41,42 the relationship between effects and the (poly)
phenols ingested and/or their derived metabolites is not con-
clusive. The questions to ask are: Which is (are) currently
accepted as the final molecule(s) responsible for the effects
after (poly)phenol consumption? Is there a consensus? It is
not clear if the effects are exerted by the ingested phenolics
and/or their microbial metabolites, and in both cases, if the
phase-II conjugates participate actively, or if the effects are
mediated by indirect signalling cascades where it is not
necessary for the direct interaction of the molecule with the
systemic target. It seems that the studies that associate the
observed activity with the simultaneous presence of circulating
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(or excreted) phenolic metabolites or their microbial deriva-
tives may be affected by many variables that prevent a well-
established cause-and-effect relationship. In this regard,
although local effects can have an impact on a systemic level,
and vice versa, the likely site of the action exerted by the (poly)
phenol ingested, i.e., gastrointestinal or systemic, could be the
first criterion to search for a possible cause-and-effect
relationship.
2.1. Effects of dietary (poly)phenols on the gastrointestinal
tract
Most (poly)phenols (90%) might exert their potential benefits
in the gastrointestinal (GI) tract because they are poorly
absorbed and are retained for a longer time than other food
compounds in the gut, where they suffer microbial
transformations.43,58 Several strategies have been developed to
improve the solubility and transport of dietary (poly)phenols
through the GI tract and their delivery efficiency to specific
intestinal regions.64 The microbial conversion of (poly)
phenols in the intestine often results in metabolites with
greater bioavailability than their precursors and, therefore,
with potential activity beyond the GI tract. These microbial
transformations are different depending on the phenolic struc-
ture (flavonoids or non-flavonoids), polymerisation degree, the
spatial configuration of the compound, and gut microbial
composition of the host.43,58 Several mechanisms of action of
the (poly)phenols and their microbial metabolites on intesti-
nal health have been investigated and summarised in the last
decade.65–70 Some of their molecular mechanisms of action
against gut inflammation are the reduction of oxidative stress,
the inhibition of the secretion of inflammatory cytokines
(TNF-α, IL-6, IL-8 and IL-1β), suppression of NF-κB activation,
positive regulation of Nrf2, modulation of immune function,
and protection of the intestinal barrier.68,70,71 Furthermore,
the intestinal barrier protection by (poly)phenols and their
metabolites indirectly limits the translocation of antigens and
bacterial pathogens and the infiltration of bacterial lipopoly-
saccharides (LPS) into the bloodstream, which could reduce
metabolic endotoxemia and host inflammation. The molecular
mechanisms (epigenetics, inflammation, mRNA expression,
and gut microbes) of several (poly)phenols have also been
reviewed, such as curcumin and resveratrol against colorectal
cancer (CRC).66,67,69 Although (poly)phenols, their microbial
metabolites, and short-chain fatty acids (SCFAs) co-exist in the
colon, it is unknown if there are in vivo synergistic interactions
that reduce inflammation and protect the gut barrier. It is also
unknown in what proportion most (poly)phenols and their
derived metabolites contribute to the protective effect on the
GI tract because most intervention studies are performed with
the food (poly)phenols. Therefore, both (precursors and
microbial metabolites) co-exist in the colon. Furthermore, the
ratio of precursor/derived metabolites varies among individ-
uals depending on their gut microbiota, whose composition is
specific at the individual level. The higher absorption rate and
anti-inflammatory activity of (poly)phenol microbial metab-
olites suggest they could play a more crucial role than precur-
sors in preserving intestinal health and mitigating gut inflam-
matory conditions. However, it could depend on the host’s
ability to produce these microbial metabolites, which differs
from one individual to another depending on their gut micro-
biota composition, which in turn depends on many factors
such as health, age, lifestyle, etc. According to this, some
(poly)phenol microbial metabolites such as urolithin A (Uro-A)
(a microbial metabolite of ellagic acid and ellagitannins) and
hydrocaffeic acid (a microbial metabolite of caffeic acid and
chlorogenic acid) have been reported to be effective in treating
gut inflammation in dextran sodium sulfate (DSS)-induced
colitis modelled in rats.72,73 Indeed, Uro-A supplementation
was more effective than pomegranate extract for ameliorating
the inflammation. Besides this, a clear effect was also observed
on inflammatory markers, antioxidant status, microbiota, and
gene expression in the DSS-pomegranate extract group. The
authors suggested that the effect could be due to either the
remaining ellagic acid or the ellagitannin fraction that could
reach the colon together with the small amount of Uro-A pro-
duced by the gut microbiota.73 Similarly, the only study of the
chemopreventive effect of ellagitannin-containing pomegra-
nate extract in CRC patients has revealed that the pomegranate
extract counterbalanced the expression of several CRC-related
genes in cancerous colon tissues. However, this effect was not
associated with the urolithin level in colon tissues or with uro-
lithin metabotypes (UMs).74 In most cases, microbial metab-
olites (e.g., Uro-A) could be the main active intestinal anti-
inflammatory and chemopreventive compounds related to the
consumption of (poly)phenols (e.g., ellagitannins) in healthy
people. However, in gut dysbiosis (e.g., inflammatory bowel
diseases (IBD) and CRC) and producers of low quantity or no
metabolites, the precursors together with a low amount of
microbial metabolites could act synergistically.
Most human studies do not unequivocally show the specific
effect of metabolites in the GI tract because they were per-
formed with their precursor (poly)phenols. However, the mole-
cular mechanisms of some metabolites have been identified
using in vitro and animal studies. In this regard, Uro-A
decreased inflammation markers (iNOS, cycloxygenase-2,
PTGES and PGE2) both in the colonic mucosa of rats after oral
administration and in an intestinal inflammatory cell model,
and upregulated tight junction proteins in HT-29 cells.73,75,76
Besides this, hydrocaffeic acid intake has been shown to
attenuate colitis by reducing inflammatory cytokines, includ-
ing TNF-α and IL-8, and dihydro ferulic acid inhibited lipid
peroxidation and DNA damage in colon mucosa after carragee-
nan-induced colitis, diminishing the expression of TNF-α,
IL-1β and IL-8 and oxidative DNA damage in the distal colon
mucosa.72 Hydroxybenzoic acids are the common microbial
degradation metabolites obtained in the gut from flavonoid
and non-flavonoid phenolics and are commonly found in most
fruits.43 Some metabolites’ potential mechanism of action,
including 3,4-dihydroxyphenylpropionic acid and 3,4-dihydrox-
yphenylacetic acid, has been investigated. These metabolites
significantly decreased the secretion of pro-inflammatory cyto-
kines TNF-α, IL-1β, and IL-6 in LPS-stimulated peripheral
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blood mononuclear cells obtained from healthy people,
suggesting their usefulness to alleviate IBD.77 According to
these studies, it was suggested that a diet rich in these metab-
olite precursors (i.e., pomegranate, artichoke, cocoa, apples,
strawberries, etc.) could exert anti-inflammatory effects and
attenuate intestinal inflammation in humans. However, in
some cases, the physiological activities of microbial phenolic-
derived metabolites could not be higher than those of their
precursor (poly)phenols. In an in vitro colon model, flavonoids
(flavanols, theaflavin, quercetin, rutin and hesperidin) of
citrus, green and black tea were catabolised to 4-hydroxypheny-
lacetic acid, 3-methoxy-4-hydroxyphenylacetic acid, 3,4-dihy-
droxyphenylacetic acid, and other catabolites with lower anti-
proliferation effects than the corresponding parent flavonoids
on colon cancer cell lines.78
The gut microbial imbalance (i.e., gut dysbiosis) has been
associated with IBD, irritable bowel syndrome, CRC, allergies,
obesity, metabolic syndrome and neurodegenerative diseases,
among others.79–81 A healthy, diverse, and stable gut micro-
biota is essential in maintaining the homeostasis of the gut
barrier and regulating the gut-brain axis.82,83 Besides other gut
bacteria such as Faecalibacterium prausnitzii and Bacteroides
thethaiotamicron, lactobacilli and bifidobacteria are considered
beneficial in human health, helping to improve gut barrier
function and the host immune system, prevent diarrhoea or
allergies, activate pro-vitamins, and modulate lipid metab-
olism.79 The impact of dietary (poly)phenols on the gut
microbial ecology and the mechanism underlying the putative
beneficial effects on the GI tract and extra-intestinal diseases
have been recently reviewed.64,84 Several (poly)phenol-rich
foods increase gut microbiota diversity, improve the relative
abundance of beneficial bacteria such as lactobacilli and bifi-
dobacteria, and inhibit the pathogenic species. However, the
precise association of (poly)phenols with benefits for the GI
tract through gut microbiota modulation has been suggested
but not unequivocally proven. In a human intervention study,
cocoa flavanols promoted the growth of lactobacilli and bifido-
bacteria (intestinal barrier protectors) and reduced C-reactive
protein (CRP) concentrations, an inflammatory blood bio-
marker and a hallmark of the acute phase inflammatory
response. Changes in CRP concentrations were significantly
linked to changes in lactobacilli counts.85 Other human inter-
vention studies showed that an ellagitannin-rich pomegranate
extract decreased plasma LBP in overweight-obese subjects,86
and patients with newly diagnosed CRC.87 Changes in LBP
were significantly associated with the increase of
Faecalibacterium, one of the main SCFA-producing bacteria,
especially butyrate.86 It is known that the gut microbiota inter-
acts with the host through microbial metabolites such as
SCFAs from dietary fibre and metabolites produced from
dietary (poly)phenols. It has been well established that SCFAs
are the primary candidates in the crosstalk between bacteria
and the intestine.88 SCFAs are an important source of energy
for colonocytes and play a significant role in regulating tight
junction proteins (claudin-1, occluding and zonula occludens-
1), critical in preserving the integrity of the intestinal
barrier.79,89 Several bacteria contribute to SCFA production.
Modulation of growth and/or metabolic activity of SCFA-produ-
cing bacteria and, therefore SCFA production, has been associ-
ated with fibre consumption and the presence of (poly)
phenols in the diet. For instance, red wine (poly)phenols sig-
nificantly increased the number of faecal lactobacilli, bifido-
bacteria, and butyrate-producing bacteria (F. prausnitzii and
Roseburia) at the expense of less desirable groups of bacteria
such as LPS producers (Escherichia coli and Enterobacter
cloacae).90 Different studies have shown that some (poly)
phenols either interfered with or enhanced these positive
effects of fibre.84 For instance, a combination of apple (poly)
phenolic fraction (epicatechin, procyanidins, and chlorogenic
acid) with apple pectin showed an additive effect on SCFA pro-
duction in rat cecum size.84,91 Conversely, strawberry ellagitan-
nins thwarted the positive effects of dietary fructooligosacchar-
ides, while anthocyanin-rich strawberry extracts enhanced the
beneficial effects of a fructooligosaccharide-rich diet.92,93
Factors such as the state of health (composition and function-
ality) of the gut microbiota and its enormous complexity of
interactions with the host show the difficulty of demonstrating
the in vitro effects of dietary (poly)phenols in the human GI
tract.
2.2. Effects of dietary (poly)phenols on systemic targets
Before entering the bloodstream, dietary (poly)phenols must
pass from the gut lumen, which is a crucial bottleneck in their
subsequent potential biological activity.2,94 Most (poly)
phenols from plant foods are glycosylated, and the attached
sugar moiety is usually released before absorption occurs. The
bioaccessibility of (poly)phenols is closely related to their
physicochemical structure and the food matrix that contains
them, which could interfere with their release ability and intes-
tinal absorption. Once in the enterocyte, the cytochrome P450
(CYP) family of enzymes catalyse phase-I reactions, involving
oxidation, reduction, and hydrolysis. Later, the aglycones can
undergo phase-II metabolism in enterocytes by enzymatic
systems like UDP-glucuronosyltransferases (UGT), acetyltrans-
ferases, glutathione-S-transferases (GST), sulfotransferases
(SULT), and catechol-O-methyltransferases. Besides this,
members of the ATP-binding cassette (ABC) superfamily are
considered gatekeepers governing (poly)phenol absorption,
their excretion, and, in many cases, their entry into target
organs.95,96 ABC transporters can limit the absorption of
(poly)phenols, their aglycones or derived metabolites by
driving efflux back into the lumen (Pgp, MRP2 and BCRP) or
transporting them from the intracellular compartment to the
bloodstream (MRP3).96–98 Once in the bloodstream, phenolic
metabolites can be subjected to additional phase-II metab-
olism, mainly in the liver, where CYP enzymes and ABC trans-
porters can also critically influence the metabolism and fate of
(poly)phenol-derived metabolites before urinary
excretion.16,98,99 Finally, the (poly)phenols not absorbed,
which can be a substantial amount of those ingested, are
metabolised by the gut microbiota, mainly in the colon. The
microbial-derived metabolites can be subjected to the same
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restrictions and metabolic actions as their phenolic precursors
(i.e., absorption, transport, etc.). The microbial metabolites are
usually excreted in the urine in high quantities, usually over
those phenolic metabolites that enter the bloodstream before
gut microbial catabolism. Overall, systemic cells can be
exposed to these gut microbial-derived phenolics rather than
their parent (poly)phenols ingested through plant foods.2,15,59,99
2.2.1. The qualitative criterion: gut microbiota metabo-
types associated with (poly)phenol metabolism. The term
“metabotype” refers to a metabolic phenotype, i.e., the differ-
ential metabolic response of individuals to nutritional or
pharmacological interventions, defined by their (epi)genetics,
physiology and/or gut microbiota composition and functional-
ity. Therefore, it is an extensive concept and can concern the
gut microbial and host metabolism and subsequent biological
activity (synthesis, transport, interaction with receptors, etc.) of
either endogenous or exogenous compounds. Molecules such
as cholesterol, glucose, and xenobiotics (dietary, pharmaco-
logical and environmental compounds), among many others,
can show distinctive metabotypes.43,59,100–103 Therefore, the
unequivocal identification of metabotypes associated with the
metabolism of (poly)phenols by the gut microbiota requires
limiting the definition to this specific context, i.e., a metabolic
phenotype that gives rise to characteristic metabolites derived
from the catabolism of specific (poly)phenols by a particular
gut microbial ecology in terms of composition and functional-
ity.59 Overall, a metabotype associated with the gut microbiota
is defined by a qualitative criterion (i.e., producer vs. non-produ-
cer of specific metabolites) and not by a quantitative criterion
(i.e., high producer vs. low producer), since the production gra-
dient could be affected by external factors (diet, motility of GI
tract, food matrix, sample collection time, etc.).43,55,59
The metabolism of many (poly)phenols, including flava-
nones, lignans, prenylflavonoids, proanthocyanidins, antho-
cyanins and stilbenes, shows high interindividual variability,
demonstrated by the presence of a metabolite production gra-
dient that gives rise to the so-called “high producers” and “low
producers” of certain metabolites.55,104–107 However, no gut
microbiota-associated metabotypes have been unequivocally
described in their metabolism.43
Flavanone metabolism, such as hesperidin, yields high and
low metabolite (hesperetin) excreters, a process mainly gov-
erned by the rhamnosidase activity of the gut microbiota
(Fig. 1).108,109 However, hesperetin is an intermediate, further
metabolised to phenolic acids (phenylpropionic, phenylacetic,
and hippuric acid derivatives), which are typical final catabo-
lites for many flavonoids.
Therefore, flavanone metabolism does not yield unique
microbial metabolites but a metabolite production gradient,
depending on the rhamnosidase activity of the individuals’
gut microbiota and the physicochemical properties of
flavanones, especially their solubility under physiological
conditions.53,104,107,108,110
Likewise, the metabolism of lignans such as the flaxseed
secoisolariciresinol diglucoside does not produce specific
metabolites but a gradient of intermediates to get enterodiol
and enterolactone, which seems to be produced by the entire
population to a greater or lesser extent.111,112 The presence of
unique enterodiol and/or enterolactone-derived catabolites,
which could be related to specific gut microbiota-associated
metabotypes, has not been identified so far (Fig. 1).43
The possible gut microbiota metabotype associated with
the metabolism of hops prenylflavonoids, such as xanthohu-
mol and isoxanthohumol, has not been sufficiently demon-
strated either. Xanthohumol can be either chemically or enzy-
matically converted into isoxanthohumol, which the gut
microbial Eubacterium limosum can demethylate to yield the
potent phytoestrogen 8-prenylnaringenin (8PN) (Fig. 1).113
However, several issues prevent a possible clustering of
individuals according to a gut microbiota metabotype
associated with the unique production of 8PN. Firstly,
the gut microbial Eubacterium ramulus can metabolise
8PN to O-desmethylxanthohumol and O-desmethyl-
α,β-dihydroxanthohumol (Fig. 1).113 Besides this, 8PN can
already be present in food products (hops and beer), and
finally, 8PN can also be formed by human cytochromes.114,115
Avenanthramides (AVAs) are phenolic alkaloids found
mainly in whole-grain oat.116 Recently, Wang et al.117 observed
interindividual variations in the metabolism of AVAs to
dihydro-AVAs (DH-AVAs) in humans (Fig. 1). These authors
identified F. prausnitzii as the individual bacterium to metab-
olise AVAs to DH-AVAs and proposed that the abundance of
this species could be helpful to stratify individuals into AVA
metabolisers and non-metabolisers after whole-grain oat
intake.117 The authors claimed the term “metabotype” to illus-
trate the above interindividual variability. However, these
results were based on a pharmacokinetic study with only 11
volunteers and 21 in vitro faecal fermentation experiments.
F. prausnitzii is one of the most abundant bacterial species in
the human intestinal microbiota of healthy adults, represent-
ing more than 5% of the total bacterial population.118 The
chronic consumption of a (poly)phenolic substrate can
increase the abundance of the microbial groups involved in its
metabolism,58,119 implying that the continuous consumption
of whole-oat could convert non-metabolisers into DH-AVA pro-
ducers; in this case by the increase of F. prausnitzii. Besides
this, many microbial groups could catalyse the reduction of
the double-bond from AVAs to DH-AVAs in the hydroxycin-
namic acid moiety since this is a relatively non-specific reac-
tion (Fig. 1).58,105,120 Therefore, it is difficult to conceive that
changes in the abundance of F. prausnitzii could be the limit-
ing step in converting AVAs to DH-AVAs in healthy adults.
Although there is interindividual variability in the metabolism
of AVAs,117 the existence of a genuine gut microbiota-associ-
ated metabotype for AVA metabolism deserves further research.
Flavan-3-ols (flavanols) and proanthocyanidins from tea,
cocoa, grapes, apples, etc., are catabolised into different phe-
nylvalerolactone derivatives.47,121–123 Although valerolactone-
derivatives are characteristic of flavanol metabolism, these
metabolites are further transformed to phenolic acid deriva-
tives, as in many other flavonoid metabolic pathways
(Fig. 1).55,124,125
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Cortés-Martín et al.55 reported several points that prevent
the identification of gut microbiota metabotypes associated
with the metabolism of flavanols. For example, the binary
response of gut microbiota metabotypes is not accomplished
in flavanols, i.e., the presence vs. absence of unique metab-
olites, which does not allow the population to be stratified as
Fig. 1 Summarised catabolic pathways of dietary (poly)phenols non-related to gut microbiota metabotypes. (A) Flavanones (hesperidin), (B) lignans
(secoisolariciresinol), (C) prenyl-flavanones (xanthohumol), (D) avenanthramides (avenanthramide-C) and (E) proanthocyanidins and flavan-3-ols
(catechin), HPP-2-ol, 1-(hydroxyphenyl)-3-(2’’,4’’,6’’-trihydroxyphenyl)-propan-2-ol; PV, phenylvalerolactone; HPV, hydroxyphenyl valerolactone;
DHPV, dihydroxyphenylvalerolactone; PVA, phenylvaleric acid; HPVA, hydroxyphenylvaleric acid; DHPVA, dihydroxyphenylvaleric acid; HPPA, hydro-
xyphenylpropionic acid; DHPPA, dihydroxyphenylpropionic acid; HPAA, hydroxyphenylacetic acid; DHPAA, dihydroxyphenylacetic acid; HBA, hydro-
xybenzoic acid; DHBA, dihydroxybenzoic acid; HA, hippuric acid; HHA, hydroxyhippuric acid. Adapted from Cortés-Martín et al.43 with permission
from Wiley, copyright March 19, 2020.
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producers vs. non-producers. As in the case of other (poly)
phenols, the production gradient (high and low producers of
valerolactone-derived metabolites) gives rise to substantial
interindividual variability, in which phase-II polymorphisms
and other variables (food matrix, flavanols polymerisation
degree, etc.) can contribute critically.55,126,127 Therefore,
despite the opinion of other researchers, strictly speaking,
there are no gut microbiota metabotypes associated with the
metabolism of flavanols. As previously suggested, phase-II
enzymes give rise to high interindividual variability and poss-
ible potential metabotypes (not associated with the gut
microbiota).53,55,128 However, these possible metabotypes
should provide a clear discriminant clustering of individuals
and not an additional gradient (i.e., high and low levels) based
on, for example, the typical glucuronidation/sulfation
ratio.55,128 The question raised in any possible gradient is
always the same: what is the cut-off to consider an individual
from one or another “metabotype”? This issue is even more
relevant when tentative “metabotypes” have been proposed
after the analysis of in vitro or in vivo samples from a few vol-
unteers (n ≈ 10–15), which is, unfortunately, the most
common scenario in those studies that recurrently use the
term “metabotype” in the context of (poly)phenol
metabolism.117,128–130 Indeed, after analysing such small
sample sizes, high and low producers could be tentatively
identified by specifying an arbitrary limit to establish such a
classification. However, in a large cohort, it could be possible
that after applying the same cut-off, these same volunteers
could be all grouped within the high producers or all of them
within the low producers. The establishment of this cut-off is
arbitrary and depends on many external factors, as discussed
in a further section. For example, for identifying genuine meta-
botypes, the sensitivity of the analytical procedure is crucial. If
the technique is not sensitive enough, especially when the
detection limit of a specific metabolite is relatively high, it
could lead to the erroneous interpretation that an individual is
a non-producer. Besides this, identifying “new” metabotypes
based on the absence of a specific metabolite in urine is ques-
tionable because polymorphisms in gut transporters involved
in phenolic-derived metabolite absorption and excretion can
affect the urine excretion profile of metabolites. Therefore, a
comparative analysis between urine and faecal excretion is
mandatory. Overall, large groups are needed to identify gut
microbiota metabotypes associated with the metabolism of
(poly)phenols.43,55,111,131
The stratification of individuals according to their gut
microbiota (poly)phenol metabotypes has been proposed to
understand individuals’ response to dietary (poly)phenols,
which could be crucial in the context of personalised
nutrition.43,119 To date, the metabotypes identified unequivo-
cally are those involved in the metabolism of isoflavones
(equol producers vs. non-producers), and ellagic acid (UMs,
including producers of only Uro-A (UM-A), producers of Uro-A,
isourolithin-A (IsoUro-A), and urolithin-B (Uro-B) (UM-B), and
urolithin non-producers (UM-0)) (check Cortés-Martín et al.43
for a comprehensive description of these metabotypes). Of
course, within each metabotype, a metabolite production gra-
dient also defines tentatively “high” and “low” producers of
metabolites. However, the same problem for establishing the
boundary between high and low metabolite producers is also
found within genuine metabotypes.43,111,132
Therefore, the concept of gut microbiota metabotypes
associated with (poly)phenol metabolism involves a qualitative
criterion with two possible putative players responsible for the
(poly)phenol health effects: (i) (poly)phenol-derived metab-
olites with distinctive biological activity and specifically pro-
duced only for some individuals, and/or (ii) the particular gut
microbial ecology in terms of composition and functionality,
associated with (poly)phenol metabolism, and harboured by
specific individuals.
2.2.1.1. Production of distinctive microbial phenolic-derived
metabolites. There are two paradigmatic examples regarding
the production of phenolic-derived postbiotics produced by
specific gut microbiota ecologies: (i) equol-producing individ-
uals (producers) and equol non-producers in the daidzein
metabolism, and (ii) urolithin-producing individuals (UM-A
and UM-B) vs. those individuals not capable of producing uro-
lithins (urolithin non-producers, UM-0) after consuming
ellagic acid (Fig. 2). Whether these phenolic-derived postbio-
tics are the final drivers in the health benefits observed upon
isoflavone- or ellagitannin-rich foodstuff consumption
deserves further research.43,59
The evidence on the role of postbiotics in human health is
well consolidated for some compounds, including SCFAs,133
but still weak for many others.43,134–137 To date, there is no evi-
dence to support a specific health benefit from producing,
qualitatively, one metabolite (e.g. equol or Uro-A) compared
with others.
While the distribution of UM-A and UM-B is critically
affected by ageing, the proportion of individuals with UM-0
(urolithin non-producers) remains constant, about 10%, from
5 to 90 years of age.131 Therefore, the relatively low number of
volunteers with UM-0 in different human studies has pre-
vented the drawing of any statistically significant conclusion
regarding the possible impact of non-producing urolithins in
the outcomes of the studies.74,119,138,139
Regarding the metabolism of isoflavones, the equol- and
ODMA-producer metabotypes have been identified so far.111 It
seems that both metabotypes are independent of each
other.140 However, as discussed for flavanols, flavanones, and
prenylflavanones, the catabolism of ODMA can also give rise to
simpler and unspecific metabolites such as phloroglucinol,
4-hydroxyphenyl propionic acid, etc. (Fig. 2), which are
common in the microbial catabolism of many other dietary
phenolics. Therefore, this fact could compromise a genuine
ODMA-metabotype in the population and might have contribu-
ted to the inconsistent results linking isoflavone metabotypes
and human health outcomes.43 The percentage of equol pro-
ducers has been estimated to be around 30% and 50–60% in
the Caucasian and Asian populations, respectively.141,142
Therefore, it could be potentially more feasible to reach stat-
istically significant differences when linking the presence or
Review Food & Function


































































































absence of equol in the results of each study. However, produ-
cing a specific microbial-derived metabolite such as equol is
linked to harbouring a particular gut microbial ecology.111,143
Therefore, whether a specific microbial-derived metabolite
exerts biological activity, dependently or not of the associated
microbiota, requires evaluating the effects upon direct admin-
istration of the metabolite.
To date, equol is the most studied phenolic-derived postbio-
tic in humans. The main evidence suggests improvement of
cardiometabolic biomarkers and, particularly, protection
against menopausal symptoms.144–154 However, the precise
mechanisms are not yet fully elucidated.43 A human trial (n =
49) described the improvement of some cardiometabolic risk
biomarkers in overweight-obese women after S-equol adminis-
tration (10 mg), showing more effects in the equol non-produ-
cer participants.149 In contrast, Hazim et al.150 described acute
vascular effects in healthy equol-producing men (n = 14) after
consuming isoflavones. The effects were associated with peak
circulating equol concentrations (although the isoflavones sup-
plement did not contain synthetic S-equol). Remarkably, equol
administration (40 mg) did not exert any effect on equol non-
producers. However, in the parallel assay, no synthetic equol
was administered to the equol-producers or isoflavones to
equol non-producers.150 This means that the acute vascular
effects of equol (dependently or not of the equol-related meta-
botype) have not been demonstrated unequivocally. Two ran-
domised placebo-controlled trials (RCT) specifically recruited
equol-producing participants to evaluate isoflavone effects on
blood pressure, vascular function,155 bone metabolism and
inflammation.156 Remarkably, the authors did not observe a
significant effect on any cardiovascular risk factor among 253
Chinese equol-producing postmenopausal women that con-
sumed isoflavones for 6 months.156 Unfortunately, whether
the same approach could have exerted some effects on equol
non-producers remains unanswered. Recently, an 8.8-years
prospective study described that serum isoflavones and equol
Fig. 2 Summarised catabolic pathways of (A) isoflavones (daidzein and genistein) and (B) ellagic acid to urolithins. The circles specifically enclose
the final urolithins for each metabotype (red, UM-B; blue, UM-A). Urolithin M5 (purple) is the only detected urolithin in UM-0. R-urolithins (pink) are
those present in individuals with specific 3-dehydroxylase activity (they can be present in both UM-A and UM-B). D(G)R, daidzein/genistein
reductase; DH(G)R, dihydrodaidzein/genistein reductase; THD(G)R, tetrahydrodaidzein/genistein reductase; CYP450, mammalian cytochrome P450;
4-HPPA, 4-hydroxyphenyl propionic acid. Adapted from Cortés-Martín et al.43 with permission from Wiley, copyright March 19, 2020.
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were associated with reduced carotid intima-media thickness
progression, mediated by sex hormone-binding globulins and
systolic blood pressure in 2572 Chinese subjects (40–75 years
old).157 However, a case-control study with pre- and postmeno-
pausal Chinese women (n = 792) only found a statistically sig-
nificant association between serum daidzein and reduced
odds of breast cancer, but not with the rest of the isoflavones
or equol.158
Urolithins, mainly Uro-A, can exert anti-inflammatory and
anti-obesity activities, preserve the intestinal barrier, modulate
the gut microbiota, and protect from oxidative stress,
among many other activities, in animal models.73,132,159–161
Besides this, physiologically relevant mechanistic in vitro
studies support the underlying molecular mechanisms
involved.18–21,162–164 However, there are no human studies to
confirm these potential effects.132 To date, there are two
human studies conducted with a commercial oral synthetic
Uro-A supplement, funded by a private company. One of them
described cellular health improvement by regulating gene
expression associated with cellular and mitochondrial func-
tion.165 The second one claimed the consumption of 500 mg
of synthetic Uro-A as the solution to achieve more plasma Uro-
A-derived conjugates than the single intake of a specific pome-
granate juice and after only 6 h,166 not enough time to achieve
a substantial conversion of ellagic acid into Uro-A, which can
take around 48 h.48,167 Besides this, walnut intake would have
yielded much more Uro-A production.168
Nevertheless, as in equol, future human trials dealing with
urolithins should consider the individuals’ UMs to evaluate the
possible role of the associated gut microbiota in the postbiotic
effects. Overall, the in vivo activity of phenolic-derived postbio-
tics cannot be discarded, but the evidence supporting their
genuine role in health is still too limited to be unquestionable.
In this regard, they could be potential biomarkers of specific
human gut microbiota metabotypes associated with the metab-
olism of (poly)phenols rather than irrefutably bioactive metab-
olites with differential impact on human health.169
2.2.1.2. Specific gut microbial ecologies, associated with
the metabolism of (poly)phenols, as possible health drivers.
An increasing number of studies encourage the clustering
of subjects into known metabotypes (i.e., metabotyping) as
a strategy to explain, at least partially, the different response
of individuals to dietary compounds, including (poly)
phenols.43,63,102,119,170–172 This approach would allow tailoring
of specific (poly)phenol-rich diets for specific individuals by
linking metabotypes to the concept of “personalised nutri-
tion”, i.e., optimising and aiming the diet individually for the
prevention of some diseases.59,119,173–176
The current evidence suggests that equol and/or ODMA
producers may have a lower cardiovascular risk than non-pro-
ducers.111 The capacity of individuals for producing equol
seems to be stable at least for 2 years,177 and the proportion
of equol production status might increase with age.178
However, despite the attempts to correlate the occurrence of
the equol- or ODMA-producer metabotypes with dietary pat-
terns and some sociodemographic characteristics of the
population, including age, education level and ethnicity, no
clear associations have been consistently found.111,179 The
association of the ODMA non-producer metabotype with
obesity in peri- and postmenopausal women has been pre-
viously suggested.180 These results agree with those observed
by Reverri et al.,181 who reported that equol and ODMA non-
producers were related to obesity. In the same line, the
inverse association between the equol producer metabotype
and obesity has been recently suggested in postmenopausal
women, using logistic regression analysis with adjustment
for lifestyle factors.182
More than 10 gut microbes have been reported to be
involved in the equol production, including Adlercreutzia equo-
lifaciens,183 Asaccharobacter celatus (now Adlercreutzia equolifa-
ciens subsp. celatus),184 Bacteroides ovatus,185 Finegoldia magna,
Lactobacillus mucosae (now Limosilactobacillus mucosae),186
Slackia equolifaciens, Slackia isoflavoniconvertens,187,188 and
Streptococcus intermedius.185 In contrast, reports on gut
microbes that specifically produce ODMA, but not equol, are
less abundant. This is the case of Adlercreutzia equolifaciens
IPLA37004, whose genome sequence suggested a deletion in a
large part of the equol operon.189
Nakatsu et al.190 found a greater abundance of the genera
Bifidobacterium and Eubacterium in equol-producers vs. non-
producers in 17 postmenopausal women after consuming
isoflavone-containing soy bars for one week. Later, Lino
et al.178 compared the relative abundance of 8 gut microbes
capable of producing equol in 1044 adult subjects.
Interestingly, the equol producing intestinal bacteria were
present in both equol producers (n = 458) and non-producers
(n = 586). However, the species A. equolifaciens subsp. celatus
and S. isoflavoniconvertens were significantly more abundant in
equol-producers vs. non-producers. Overall, a clue from this
study could be the existence of a possible threshold abundance
of A. equolifaciens subsp. celatus and S. isoflavoniconvertens
necessary to produce equol from daidzein.
A cross-sectional study described the difference in the gut
microbiota between the equol-producer and non-producer
metabotypes in Chinese people (n = 99).143 Unfortunately, this
study did not consider the ODMA metabotype as an important
feature of daidzein metabolism. No significant difference in
bacterial richness was found between the equol-producer and
non-producer metabotypes, and the equol-producer metabo-
type was not affected by the intake of isoflavones for 3 days.
Although this is too short an isoflavone intervention to modify
a metabotype status, this finding agrees with Yoshikata
et al.,191 who reported that equol production might not
depend on the quantity of equol-producing bacteria but the
type of these bacteria since equol-producing bacteria were
identified in 56 women but only 13 produced equol (i.e., not
all strains within the genus identified as potential equol pro-
ducers are actually capable of metabolising daidzein to
produce equol). However, unlike Zheng et al.,143 Yoshikata
et al.191 described a higher microbial diversity in equol produ-
cers. Besides this, a previous study reported that isoflavone
consumption for one month did not induce the ability to
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produce equol in postmenopausal women.192 These results
suggest that the conversion of non-producing individuals into
equol producers seems to be unlikely.
The equol-producer metabotype shows a higher abundance
of the species A. equolifaciens and Bifidobacterium bifidum than
the non-producer.143 Besides this, the equol-producer metabo-
type showed a higher abundance of Prevotella, Megamonas,
Allistipes, Desulfovibrio, Collinsella, and Eubacterium genera. In
contrast, the equol non-producer metabotype was enriched in
the family Lachnospiraceae, the genus Eggerthella and several
species from Ruminococcus and Bacteroides. Also, the authors
found statistically significant associations between the equol-
producer metabotype and lower prevalence of dyslipidaemia
vs. non-producers (27% vs. 50%).143 However, no associations
between microbial composition and functionality with body
mass index (BMI), smoking habit, age, and gender were found.
Other cross-sectional studies in Chinese postmenopausal
women193 and Japanese men194 have reported better cardio-
vascular health profiles for both equol and ODMA producers
than non-producers. Sekikawa et al.195 found proportionally
inverse associations between equol-producing status (non-pro-
ducers, low and high) and white matter lesion, but not the
amyloid-beta deposition, in 91 normal cognitive elderly
Japanese. Unfortunately, the gut microbiota of the participants
was not analysed.
A recent study compared faecal samples from 20 individ-
uals with sporadic colorectal adenomas vs. 20 without prolif-
erative lesions and observed the presence of Parabacteroides
distasonis, Clostridium clostridioforme, and Pediococcus pentasa-
ceus only in controls, while Bacteroides fragilis and Prevotella
melaningenica were present only in those subjects with colorec-
tal adenomas.196 Remarkably, the authors found undetectable
or deficient equol levels in individuals with colorectal adeno-
mas vs. control and suggested that equol production could
determine a milieu able to contrast the development of
colonic mucosa proliferative lesions.196 Obviously, it is not
known whether precancerous signalling could modulate the
gut microbiota or a specific gut microbiota played a possible
role in the development of lesions, or both. Thus, as in other
cross-sectional studies, the causality role of the gut microbial
ecologies cannot be unambiguously assumed.
The specific response of individuals, according to their
equol and/or ODMA producing status after dietary intervention
with isoflavones, are less abundant. Recently, Hayashi et al.197
reported that the interaction of aerobic exercise and equol pro-
duction status plays an essential role in improving central
artery compliance in postmenopausal women. However, the
assay was not a crossover, and the sample size was relatively
small (27 females performed exercise vs. 16 females did not).
Reverri et al.198 described the improvement of endothelial
function, but not inflammatory biomarkers, independently of
the equol and/or ODMA production status of 17 postmenopau-
sal women and men over the age of 45 years at cardiometa-
bolic risk after consuming isoflavones. The same authors dis-
tinguished ODMA-only and equol + ODMA producers from
non-producers, according to the serum metabolome of the
same volunteers, and found a lower metabolic risk in those
producer individuals than non-producers.181 Although it was a
randomized and crossover study, the sample size (n = 17) and
the absence of a placebo could limit the scope of these results.
A RCT with soy protein supplementation (n = 50) vs.
placebo (n = 43) for 2 years in men following radical prostatect-
omy has recently reported no effects on body weight, blood
pressure, total serum cholesterol, iron status parameters,
calcium, phosphorus, and thyroid hormones.199 Interestingly,
the stratification of subjects on equol production status in the
soy group revealed that body weight increased in equol produ-
cers compared with non-producers. Besides this, both systolic
and diastolic blood pressure decreased only in the equol non-
producers.199 Overall, these results suggest that the capacity to
produce equol in middle-aged to older men seemed to be a
disadvantage and agree with Usui et al.149, who observed
higher cardioprotective effects in the subgroup of women
equol non-producers after consuming 10 mg S-equol. However,
it should be noted that most participating men were under
medication (mainly taking lipid-lowering and anti-hyperten-
sive drugs, not considered as covariates in the analyses),199
which might affect the gut microbiota and determine the soy
effects and equol production. Overall, the possible influence of
medication on equol production and isoflavone effects agree
with recent results observed for urolithins in polymedicated
metabolic syndrome patients after consuming pomegranate.139
While the percentage of equol producers in Caucasians has
been estimated to be about 30%,141 the proportion of equol
producers was much higher in the study of Bosland et al.199
As commented above, the metabolism of ellagitannins and
ellagic acid to produce (or not) distinctive UMs is critically
affected by ageing, as reported in a large cohort (n = 839),
mainly Caucasians and aged from 5 to 90 years.131 The percen-
tage (10%) of urolithin non-producers (UM-0) remains con-
stant in the range from 5 to 90 years of age. In contrast, the
proportion of UM-A at an early age (85%) progressively
decreases up to 55% from 40 to 90 years of age, concomitant
with an increase of UM-B from 15% up to 45%. The shift from
UM-A to UM-B was more evident from 25 to 35 years of age,
and from that age, the proportion of UM-A and UM-B (55%
and 45%, respectively) remains approximately unaltered.131
Although UMs are stable within individuals at a certain age, a
challenge of a high dose of ellagitannins for 3 weeks can shift
some specific individuals from apparent UM-0 to either UM-A
or UM-B.119 However, we think these individuals were not
genuine UM-0 but very low urolithin producers, in which uro-
lithin production was below the limit of detection or their gut
microbiota was more sensitive to ellagitannin consumption
than other real UM-0 individuals. To date, no clear association
between UMs and diet, sex, or ethnicity has been reported.
Despite preliminary observations associating UM-B with
higher BMI and gut dysbiosis,200,201 this was not unequivocally
confirmed in a large cohort (n = 839) that included healthy vol-
unteers and patients.131 On the other hand, in a recent study,
gut microbiota and UM distribution in mothers were changing
through the 1-year follow-up postpartum to resemble the dis-
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tribution in the general population previously described.138
The decrease in the percentage of overweight mothers with
UM-B was concomitant with the increase of normoweight
mothers with UM-A over time. Although the correlation
between UM-B and obesity cannot be unequivocally estab-
lished, the results of that study suggest that the UM-B dysbio-
sis-prone metabotype could be a potential contributor to
obesity.
The interindividual variability in urolithin production has
been related to some dissimilarity in the gut microbiota. Pure
cultures of Gordonibacter species can metabolise ellagic acid
into different urolithins202 and are positively associated with
Uro-A and UM-A in faeces and urine.63,168 In contrast, the
occurrence of IsoUro-A, Uro-B, and UM-B are inversely associ-
ated with faecal concentrations of Gordonibacter spp.63,170
Ellagibacter isourolithinifaciens, another human gut bacteria of
the family Eggerthellaceae, converts ellagic acid into IsoUro-A
and is positively associated with IsoUro-A, Uro-B and
UM-B.63,203,204 Gordonibacter increase has been described in
adults at cardiovascular risk (n = 42) that consumed a diet con-
taining whole walnuts for 2 weeks compared with a standard
Western diet in a crossover design.205 Although the authors
suggested that this shift might be involved in the underlying
mechanisms associated with the cardiovascular benefits of
walnut consumption, no direct link between Gordonibacter and
any risk marker was provided. In contrast, in another study,
faecal Gordonibacter concentration positively correlated with
HDLc and negatively with both plasma glucose and VLDLc
levels in overweight-obese-metabolic syndrome volunteers con-
suming pomegranate extract or nuts.170 Lower abundance of
Gordonibacter among other bacteria was also observed in active
Crohn’s disease.206 Du et al.207 reported a higher abundance
of the genera Scardovia, Lactobacillus, Gordonibacter, and
Phascolarctobacterium in 40 Chinese patients with multiple
system atrophy compared with healthy controls (n = 40). The
authors found a positive statistical association between
Gordonibacter and the scale for Parkinson’s disease autonomic
dysfunction (r = 0.195, P = 0.011).207 However, the authors
acknowledged that their cross-sectional study did not reveal
any causal relationship between microbiota and multiple
system atrophy. In the case of Ellagibacter, this genus has been
reported to increase after consuming a symbiotic drink (pro-
biotics plus dietary fibre) by healthy postmenopausal Korean
women (n = 37) and was inversely associated with the partici-
pants’ BMI.208 However, the trial was not placebo-controlled
nor crossover, limiting the scope of the results. Overall, there
is still a low number of studies on the role of Gordonibacter
and Ellagibacter in human health. Besides this, finding
specific associations between some genera or species and
some risk factors might not be enough evidence to prove the
role of such microbial groups in health.
The comparison of the human gut microbial ecologies
associated with UMs has been reported in healthy normo-
weight, overweight, and obese individuals (n = 249).63 Unlike
the equol-producer and non-producer metabotypes that did
not show a significant difference in bacterial richness in a
recent study,143 UM-0 showed lower diversity and richness
than UM-A and UM-B subjects.63 Besides this, UM-0 was also
characterised by a lower abundance of the genera
Phascolarctobacterium, Bilophila, Alistipes, and Butyricimonas
than UM-B and UM-A. Remarkably, UM-B showed a higher
abundance of the Coriobacteriia class compared with UM-A
and UM-0, which was positively associated with total chole-
sterol (Tchol), LDLc, and BMI.63,209,210 For example, the genus
Slackia (belonging to the Coriobacteriia class), whose abun-
dance was increased in UM-B vs. UM-A, correlated with Tchol,
LDLc, apolipoprotein-B, and non-HDL-cholesterol levels. In
contrast, the family Eubacteriaceae, which was increased in
UM-A vs. UM-B, was positively associated with apolipoprotein-
A. UM-B individuals also presented a higher abundance of
some pro-inflammatory microbial groups vs. UM-A, including
Methanobrevibacter, Parvimonas, Gammaproteobacteria and
Methanosphaera.63 These differences in the gut microbial ecol-
ogies between UM-A and UM-B support previous results
showing higher cardiometabolic risk in overweight-obese
UM-B individuals vs. UM-A and UM-0.119,170 Indeed, corre-
lations between baseline CVD risk markers and urolithins
were found in overweight-obese individuals. Uro-A (primarily
present in UM-A) was positively correlated with apolipoprotein
A-I and intermediate-HDLc, while Uro-B and IsoUro-A (charac-
teristic from UM-B) were positively correlated with Tchol,
LDLc, apolipoprotein B, VLDLc, IDLc, oxLDL and the apolipo-
protein B : apolipoprotein A-I ratio. In metabolic syndrome
patients, Uro-A only correlated inversely with glucose.170
It is known that the gut microbiota is significantly altered
during pregnancy and after childbirth.211 Interestingly,
Cortés-Martín et al.138 described that the restoration capacity
of the gut microbiota and the anthropometric values of
mothers up to 12 months after delivery depended on
their UM. Through the 1-year follow-up postpartum,
UM-A women normalised their gut microbiota and anthro-
pometric values to a greater extent than UM-B. For example,
Methanobrevibacter and Olsenella reduction were correlated
to waist reduction, and reduction of Clostridiaceae,
Clostridium sensu stricto, and Anaerobacter correlated to the
reduction of waist-to-hip ratio, BMI, and waist.138 These
results also suggest that UM-B, in contrast to UM-A, was
associated with a dysbiotic-prone microbial ecology and more
resilient to change the microbial and anthropometric profiles
during postpartum.
Recently, Cortés-Martín et al.212 explored the possible par-
ticipation of UMs, along with other factors, in the prevalence
of obesity in a cohort of children and adolescents (n = 415). A
statistical ordinal logistic model revealed that overweight-
obesity prevalence was related to being a young boy (9–12 years
old) with either UM-B or UM-0, low adherence to the
Mediterranean diet (KIDMED score) and high contribution of
a specific consortium of 24 single-nucleotide polymorphisms
(SNPs) from a total of 53 SNPs related to obesity and cardiome-
tabolic diseases. In contrast, every variable (sex, diet, UMs,
SNPs, age, physical activity, etc.) was not independently associ-
ated with overweight-obesity.212
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The gut microbial ecologies of UMs have been reported to
be differentially modulated upon consumption of walnuts for
just 3 days.213 After consumption, the genera Bifidobacterium,
Blautia, and some gut microbes of the Coriobacteriia class,
including the genus Gordonibacter, increased exclusively in
UM-B. In contrast, UM-A was less sensitive to walnut consump-
tion, and some members of the Lachnospiraceae family
decreased only in UM-A individuals.213
In the line of the UM-depending response of individuals to
(poly)phenol consumption, for the first time, González-Sarrías
et al.119 described the improvement of a panel of cardiometa-
bolic risk biomarkers in UM-B individuals, but not in UM-A. In
fact, no statistically significant effects were observed before
clustering individuals according to their UM. Furthermore, no
significant correlations were found between faecal urolithins
excretion and improvement of CVD risk markers. However,
urinary excreted urolithin conjugates significantly correlated
with improvement of CVD risk markers in UM-B individuals,
i.e., reduction of Tchol, LDLc, and non-HDLc correlated with
urinary excretion levels of Uro-A metabolites, and changes of
LDLc also correlated with both Uro-A and IsoUro-A + Uro-B
conjugates. However, in UM-A individuals, where CVD risk
markers did not change, no correlations were found.
Despite these correlations with CVD risk markers, other
studies failed to find a significant correlation between uro-
lithins occurrence in plasma, urine, faeces or colonic tissues
and cancer-related markers and metabolic endotoxemia in col-
orectal cancer patients (n = 45),74,87 metabolic endotoxemia in
overweight-obese individuals (n = 49),86 and the blood lipid
profile in healthy subjects (n = 32).214
Recently, Cortés-Martín et al.139 described that UMs distri-
bution was altered in polymedicated metabolic syndrome
patients. The gut microbiota of these patients was in dysbiosis,
mainly in hypertensive patients with an overabundance of LPS-
producing members of the Enterobacteriaceae family.215 A
RCT and crossover trial showed that the polymedication of the
patients determined the prebiotic effect of an ellagitannin-rich
pomegranate extract as a crucial variable. The metabolic endo-
toxemia slightly but significantly improved in all the patients
after consuming the extract. However, the soluble intercellular
adhesion molecule-1 (sICAM-1) only improved in those
patients consuming lipid-lowering drugs (LL-), and the
patients’ medication clearly determined the modulation of the
gut microbiota. In this regard, the genus Lactococcus increased
in patients consuming antidiabetic (AD-), LL- and anti-hyper-
tensive (HP-) drugs, Bifidobacterium increased in LL- and AD-
consuming patients, and Clostridium cluster XIVa decreased in
non-LL- and non-HP-consuming patients. Urolithin pro-
duction (type and amount) was not associated with the effects
observed.139
Overall, the current evidence, albeit still low, suggests that
the gut microbial ecology of UM-A could be “protective”, while
UM-B could be a potential dysbiotic-prone metabotype to car-
diometabolic impairments.43,63 In general, the lack of clear
associations between circulating or excreted urolithin deriva-
tives (and other phenolic-derived metabolites) and specific
effects can be somewhat logical due to the highly variable
turnover of these metabolites in the bloodstream and other
reservoirs.
2.2.2. The quantitative criterion: the production gradient
of (poly)phenol-derived metabolites. Another crucial aspect to
be considered to identify or explain the (poly)phenols’ health
effects is the production gradient of the main bioactive metab-
olites that can reach the circulation and systemic tissues and
exert their potential benefits after (poly)phenols intake.
Table 1 shows representative human studies that performed
quantitative assessments of circulating and/or excreted pheno-
lic-derived metabolites to correlate health outcomes.
As commented before, the metabolism of some classes of
polyphenols, including prenylflavonoids, flavanones, flavan-3-
ols, lignans, ellagitannins and isoflavones, yields a high varia-
bility of metabolites. Therefore, the definition of “low and
high producers” has been commonly used to stratify those
individuals capable of producing a high or low amount of
metabolites, respectively.43,55,62,104,105,166,195,199,216–218
However, as previously mentioned, this cut-off concen-
tration is arbitrary and conditioned by external factors, includ-
ing the lag period between the last intake of (poly)phenolic
precursor and the sample analysis, the sensitivity of the
analytical procedure and the food matrix. Regarding food
matrix effects, flavanone metabolism is a paradigmatic
example. The amount of phenolic-derived metabolites in flava-
none metabolism is dramatically affected by their solubility.
Encapsulation and micronisation of flavanones increase their
excretion in subjects, including the so-called “low hesperetin
producers”.219
Recently, the gut microbiota metabolism of eriocitrin, a
soluble flavanone mainly present in lemon, has been reported
to yield much higher plasma and urinary concentrations of
metabolites (eriodyctiol, homoeriodyctiol, and hesperetin)
than hesperidin.107 Therefore, the cut-off for being high or low
producers will significantly depend on the solubility of the fla-
vanone. Overall, the consumption of soluble flavanone-rich
sources could be a strategy to enhance the metabolite pro-
duction of those low-flavanone metabolite producers and
provide a sufficient circulating concentration metabolite
threshold to exert health benefits even in low producer
individuals.107
There is a certain consensus regarding the intake of some
specific (poly)phenols such as epicatechin, hydroxytyrosol and
quercetin, among others, and health effects. However, the
final driver in the health effects (a specific phenolic-derived
metabolite or a mixture) has not been clearly identified.
Besides this, and very importantly, the minimum concen-
tration necessary for a specific (poly)phenol to exert health
benefits, and even less in the case of its derived metabolites, is
unknown. In this line, many trials, mainly based on the pres-
ence-absence of phenolic and dose–response studies, suggest
that phenolic-derived metabolites that, as expected, are
increased in plasma (or urine) after intake could be related to
the health outcomes observed. However, among the vast
number of studies dealing with (poly)phenols and health, only
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Table 1 Representative human studies that performed quantitative assessments of circulating and/or excreted phenolic-derived metabolites to cor-
relate health outcomes
Source and (poly)phenol
classes ingested Design of the study Health outcome
Phenolic-derived
metabolites evaluated Main correlations Ref.
Studies that did find a correlation
Flavanol-rich cocoa drink
(100 mL) with high (176 to







study. Healthy adults (n = 11).
Duration: acute (2 h). Wash
out (WO): 1 day
↑NO species and ↑FMD at
2 h after ingestion of 176 to
185 mg flavonols










Black tea (5 cups per d of
250 mL). Detailed (poly)
phenolic content not
provided
RCT and crossover. Adults
with mild hyperlipidaemia (n
= 21). Duration: acute (5 h)
and chronic (4 weeks). No
WO period
Significant increase in FMD
response after 4-week
consumption of black tea,
but not acutely
Urinary 4-O-methylgallic
acid after 5 h and 4 weeks
↑4-O-Methylgallic acid
excretion was inversely
associated with the change




(300 mL; high or low
flavanol content, 917 and





Healthy male adults (n = 16).
Duration: acute study
(assessments at 1, 2, 3, 4, and
6 h after a single-dose). WO: 2
days
Acute significant transient
increase of the FMD
response at 1–4 h after oral
ingestion of the high-
flavanol-rich cocoa drink,














Curcumin (1 or 4 g d−1) RCT, double blind, placebo-
controlled. Elderly subjects (n
= 36). Duration: 1 and
6 months
Consumption of curcumin






were correlated with slight
increases in Tchol after
1 month
223
Breakfasts rich in olive oils
with different phenolic








(n = 21). Duration:
postprandial study
(assessments at 1 and 2 h
after a single-dose). WO: 1
week
Plasma concentrations of the
procoagulant activated factor
VII (FVIIa) increased less
and PAI-1 activity decreased
more 2 h after the high-








of the high phenol olive
224
Olives (approximately






male adults (n = 8). Duration:
acute study (assessments at 1,
2, 3 and 4 h after a single-
dose)
↑Plasma total antioxidant
potential (TAP) at 2 h
Total phenolic compounds
in plasma






EGCG (200 mg in 300 mL of
water).
RCT, crossover. Healthy male
adults (n = 12). Duration:
acute study (assessments at 2
and 5 h after a single-dose). 1
week of WO
↑Plasma S-nitrosothiols,
plasma nitrite, and urinary
nitrate after quercetin and
epicatechin intake. EGCG
did not alter any of the






















Two types of olive oils
(25 mL; 22 g d−1) distributed
over 3 meals. (Poly)phenol
classes: phenolic alcohols,










both olive oil consumption





Plasma oxLDL, but not
other oxidation markers,
were negatively correlated
with the sum of phenols in
LDL
228
Orange juice or control
drink plus hesperidin
(500 mL containing 292 mg





overweight male adults (n =
24). Duration: acute study
(assessments at 6 h after a
single-dose). WO: 3 days










Cocoa (250 mL; containing
2, 5, 13, or 26 g of cocoa)






Healthy older adults (n = 23).
Duration: acute study
(assessments at 1 and 2 h
after a single-dose). WO: 3
days
↑FMD at 1 and 2 h, after the
intake of 5, 13, and 26 g
cocoa
Plasma epicatechin ↑Serum total epicatechin
correlated with ↑FMD at 1
and 2 h
230
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classes ingested Design of the study Health outcome
Phenolic-derived
metabolites evaluated Main correlations Ref.
Blueberry drinks (500 mL;
containing 766, 1,278, or






Healthy male adults (n = 10).
Duration: acute study
(assessments at 1, 2, 4, and
6 h after a 766 mg single-
dose)
Biphasic time-dependent
significant increase in FMD
at 1–2 and 6 h after
consumption of
766–1791 mg total blueberry
polyphenols
Plasma phenolic acids and
aromatic compounds (n =
32)
↑Vanillic and benzoic acids
at 1–2 h and hippuric,
hydroxyhippuric, and
homovanillic acids at 4–6 h
were correlated with ↑FMD
231
Quercetin (200 or 400 mg
d−1)
RCT, double-blind. Healthy
adults (n = 15). Duration:
acute study (assessments at 2
and 5 h after a single-dose).
WO: 1 week
Time-dependent increase in
brachial artery diameter after
400 mg of quercetin intake.
















adults (n = 31). Duration: 30




















either normal or high
concentrations of
polyphenols (299 and





obese adults (n = 100).
Duration: 12 weeks. WO: 7
weeks
The intake of both orange
juices significantly protected
against DNA damage and
lipid peroxidation, modified
several antioxidant enzymes,
and reduced body weight







activity, but not with CoQ9,





Mixed nuts (30 g d−1). (Poly)
phenol classes: ellagitan-
nins and procyanidins
RCT, 2-arms parallel. Adults
with at least three metabolic
syndrome risk factors (n =



















parallel. Healthy adults (n =
100). Duration: acute study
(assessments at 1 and 2 h; n =
5) and chronic (1 month)
Acute and chronic cocoa
flavanol consumption →





epicatechin and its related
metabolites
↑Plasma flavanols at 2 h
and after 1 month was
correlated with ↑FMD
236
Cranberry juices (450 mL;
containing 409, 787, 1238,






Healthy male adults (n = 10).
Duration: acute study
(assessments at 1, 2, 4, 6 and
8 h after a single-dose). WO: 1
week
Acute cranberry juice
consumption → ↑FMD with
a peak at 4 h and maximal
effects with juice containing
1238 mg of total (poly)
phenols
Plasma phenolic acids and







ferulic acid 4-O-sulfate and
homovanillic acid sulfate
correlated with ↑FMD (all
time-points)
237
Soy isoflavones (80 mg
aglycone equivalents)
RCT, double-blind, crossover.
Healthy male adults equol
and non-equol producers (n =
14 each group). Duration:
acute study (assessments at 6




equol producers at 24 h, but











Resveratrol (150 mg d−1) RCT, double-blind, crossover.
Adults with type 2 diabetes (n





were not affected by
resveratrol treatment, while
intramyocellular lipid
content increased in type 2
diabetes, muscle fibres and
SBP tended to decrease






Resveratrol (75, 150 or
300 mg)
RCT, double-blind, crossover.
Adults with type 2 diabetes (n
= 36). Duration: acute study













Coffee drink (50 mL;




RCT, crossover. Healthy male
adults (n = 15). Duration:
acute study (assessments at 1,
3 and 5 h after a single-dose).
1 week of WO period
Biphasic time-dependent
significant increase in FMD
at 1 and 5 h after low and
high dose of CGA







depending on the time
frame
240
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classes ingested Design of the study Health outcome
Phenolic-derived
metabolites evaluated Main correlations Ref.
Pomegranate extract (450 g
per capsule); 1st dose = 1
capsule per d (160 mg total
phenolics) and 2nd dose = 4






obese or overweight adults (n
= 49). Duration: 3 weeks each




reduction of a range of CVD
risk biomarkers, but only in
UM-B subjects
Faecal, urinary and plasma
urolithins
↑Urolithins correlated with





↓LDLc also correlated with
↑IsoUro-A + Uro-B
119



























male adults (n = 18).
Duration: acute study
(assessments at 4 h after a
single-dose)








metabolites (n = 13) in
plasma
↑(Epi)catechin metabolites








Red raspberry drinks (200 or
400 g containing 201 or










Healthy male adults (n = 10).
Duration: acute study
(assessments at 2 and 24 h
after a single-dose). WO: 1
week
↑FMD at 2 and 24 h after
consumption of the 200 and
400 g red raspberry drinks
Circulating ellagitannins







(n = 59) in plasma
Plasma ellagic acid (4.6
nM) at 2 h (after 200 and
400 g red raspberry), and
Uro-A-3-glucuronide and
Uro-A-sulfate at 24 h (41
nM) (only after 200 g)
correlated with ↑FMD. No
association was found
between FMD and 67
circulating phenolic
metabolites (120 μM at
24 h)
243
Wild blueberry drinks (11 g






RCT, 2-arms parallel, double-
blind. Healthy adults (n = 20
in each arm). Duration: acute
(2 h) and chronic (1 month)








metabolites (n = 63)
14 and 21 anthocyanin
plasma metabolites




extract (116 mg, 75 g
berries) or whole fruit








parallel. Healthy male adults
(n = 66). Duration: acute (2 h








metabolites (n = 63)
20 metabolites after Aronia
extract consumption and
5 metabolites after
consumption of the whole
fruit correlated with acute
and chronic ↑FMD
245
Red grape pomace drink
(250 mL; containing 1562 g






RCT, crossover. Healthy male
adults (n = 12). Duration:
acute (3 h after single-dose),
postprandial (5 h after the














Only gallic acid correlated




Blood orange juice or a
sugar-matched control drink




trial. Overweight men and
women (n = 15). Duration: 2
weeks. WO: 1 week
↑FMD after blood orange
juice consumption. Blood










were correlated with ↑FMD
247
Studies that did not find a correlation
Black tea (900 mL; 12.9 and
13.3 mg dL−1 of total cate-
chin and 150 and 163 mg
dL−1 of total (poly)phenols
for the freeze-dried and
freshly brewed tea, respect-
ively). (Poly)phenol classes:
flavanols
RCT, crossover. Patients with
stable coronary artery disease
(n = 66). Duration: acute
(450 mL) and chronic studies
(assessments at 2 h after a
single-dose and after 4 weeks
with daily dose). No WO
period
Black tea acute and chronic
consumption did not
improve plasma antioxidant
capacity and did not reduce







Changes in catechin levels
did not correlate with
changes in endothelial
function, plasma markers
of oxidative stress, or CRP
248
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classes ingested Design of the study Health outcome
Phenolic-derived
metabolites evaluated Main correlations Ref.
EGCG (150 mg twice daily) RCT, double blind, crossover.
Patients with coronary artery
disease (n = 42). Duration:
acute and chronic studies (2 h
after a single-dose and after 2
weeks with daily dose). WO: 1
week
↑Brachial artery FMD two
hours after the first dose of
300 mg of EGCG, but was
similar to baseline after 2
weeks of treatment (14 h
after the last dose)




Quercetin (150 mg d−1) RCT, double-blind, crossover.
Overweight or obese adults
with metabolic syndrome
traits (n = 93). Duration: 6
weeks. WO: 5 weeks
↓SBP, pulse pressure, hs-
TNF-α, serum HDLc, oxLDL
and hs-CRP (but only in
subjects with baseline











chocolate (27 g d−1; contain-
ing 850 mg flavan-3-ols
(90 mg epicatechin) +







with type 2 diabetes mellitus
patients (n = 93). Duration: 1
year
Equol producers (n = 17) had
larger reductions in DBP,
mean arterial pressure, and
PWV, compared with non–
equol producers (n = 30)
after flavonoid intervention









be inversely correlated with
DBP only in the equol




high or low punicalagin/





patients (n = 52). Duration:
intake of pomegranate extract















urolithins detected in the





Green tea beverage, green
tea extract, or isolated EGCG
(442 mL containing 200 mg
of EGCG). (Poly)phenol
classes: flavanols
RCT, crossover. Healthy male
adults (n = 50). Duration:
acute study (assessments at
2 h after a single dose). WO: 3
days
FMD significantly improved
after consuming green tea
containing 200 mg EGCG,
but not after green tea







the total catechin plasma
levels and changes in FMD
were observed
253
Pomegranate extract (450 g
per capsule); 1st dose = 1
capsule per d (160 mg total
phenolics) and 2nd dose = 4






obese or overweight adults (n
= 49). Duration: 3 weeks each
dose. WO: 3 weeks
The highest pomegranate
extract dose significantly
reduced plasma LBP levels
Faecal, urinary and plasma
urolithins
No correlation between




high or low punicalagin/





Colorectal cancer patients (n
= 35). Duration: from 5 to 35
days before surgery
↓LBP levels after daily
consumption of
pomegranate extract rich in
punicalagin
Concentration of ellagic
acid and urolithins in
plasma, urine and colon
tissues
No correlation with LBP
levels and any specific











medication (n = 50). Duration:
4 weeks. WO: 4 weeks
Pomegranate effects
depended on the patients’
medication. ↓Plasma sICAM
levels was found only in LL-
patients. ↑Lactococcus in AD-,
LL- and HP-patients,
↑Bifidobacterium in LL- and
AD-, while ↓Clostridium XIVa
in non-LL- and non-HP-
patients
Concentration of urolithins
in plasma, urine and faeces
No urolithin was
associated with any
microbial group or plasma
inflammatory-metabolic
biomarker (sICAM-1,
ghrelin, peptide YY TNF-α,
leptin, adiponectin,
sVCAM-1, RBP4, GLP-1,




8-OHdG, 8-hydroxydeoxyguanosine; AD-, patients under antidiabetic medication; ADP, adenosine-5′-diphosphate; BMI, body mass index; BDNF, brain-derived
neurotrophic factor; CGA, chlorogenic acid; CoQ, coenzyme Q; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; EGCG,
epigallocatechin gallate; FMD, flow-mediated dilation; GAE, gallic acid equivalents; GLP-1, glucagon-like peptide-1; HDL, high density lipoprotein; HDLc, high
density lipoprotein cholesterol; HGF, hepatocyte growth factor, HOMA-IR, homeostatic model assessment of insulin resistance; HP-, patients under anti-
hypertensive medication; ISI, insulin sensitivity index; LBP, lipopolysaccharide-binding protein; LDL, low density lipoprotein; LDLc, low density lipoprotein
cholesterol; LL-, patients under lipid-lowering medication; LPO, lipid peroxide; MCP-1, monocyte chemoattractant protein-1; NO, nitric oxide; oxLDL, oxidized
LDL; PAI-1, plasminogen activator inhibitor type-1; PGF2α, prostaglandin F2 alpha; PWV, pulse-wave velocity; RCT, randomised control trial; SBP, systolic blood
pressure; RBP4, retinol-binding protein-4; sICAM-1, soluble intercellular adhesion molecule-1; SOD, superoxide dismutase; sVCAM-1, soluble vascular adhesion
molecule-1; TAP, total antioxidant potential; Tchol, total cholesterol; TNF-α; tumour necrosis factor-α; UM, urolithin metabotype; WC, waist circumference; WO,
wash-out.
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a few human studies have explored correlations and/or associ-
ations between the reached concentrations of these circulating
or excreted metabolites and health outcomes (Table 1). Most
of these studies that have observed a significant correlation
with specific circulating phenolic-derived metabolites belong-
ing to acute studies where the variation in the concentration-
time profile of these circulating metabolites is more controlled
than chronic studies.
Thus, to date, improvements in flow-mediated dilation
(FMD) have been correlated with changes in plasma flavanols
and derived metabolites such as epicatechin and its glucuro-
nides following flavanol-rich cocoa consumption.220,222,230,236
On the contrary, significant increases in plasma catechin
metabolite levels did not correlate with changes in endothelial
function, plasma markers of oxidative stress, or CRP after
acute and chronic black tea or pure EGCG consumption.248,249
These findings suggest that other (poly)phenolic components
of tea may influence vascular health or, perhaps, it is another
example of the food matrix effect. In this regard, the increase
in urinary 4-O-methyl gallic acid was inversely associated with
the change in FMD responses after 4-weeks of black tea
consumption.221
Other studies have also shown acute correlations between
FMD and several phenolic acid metabolites such as vanillic,
benzoic and hippuric acids, and ferulic and caffeic acid sul-
fates, among others, after anthocyanin-rich berry
intake.231,237,244,245 Surprisingly, the same authors associated
the improvement of FMD in 10 subjects after red raspberry
intake with the presence of plasma ellagic acid (4.6 nM) and
Uro-A conjugates (41 nM), but not with the pool of plasma
phenolic acid metabolites that reached 120 μM.243 Overall, it is
likely that associations will be found between plasma metab-
olites that increase after consuming the corresponding (poly)
phenolic precursor and acute specific effects such as FMD
improvements. However, these associations are usually lost in
longer studies, even if the effects are also observed. Statistical
associations do not necessarily involve causality or clinical
relevance. In this regard, the approach of these authors to
prove the link between FMD effects and circulating metab-
olites should be highlighted. They injected the equivalent dose
of the pool of metabolites found in human plasma into mice
and observed an improvement of FMD in mice, proving the
causality role of anthocyanin-derived metabolites.244
Urinary excreted flavanone metabolites such as hesperetin
3′-O-glucuronide, and hesperetin 7-O-glucuronide have also
been correlated with relative FMD improvements in overweight
subjects after drinking orange juice.247 As expected, flavanone
metabolite excretion increased after orange juice intake.
However, whereas orange juice might improve FMD, there is
no proven causality between urinary flavanone metabolite
excretion and observed effects.
Other acute or postprandial studies have reported corre-
lations between some health outcomes and circulating metab-
olites such as hesperetin concentrations and changes in micro-
vascular endothelial reactivity after both orange juice and
control drink plus hesperidin intake,229 quercetin-3′-O-glucuro-
nide concentrations and an increase in brachial artery dia-
meter after 400 mg of quercetin intake,232 hydroxytyrosol con-
centrations with the reduction of the pro-coagulant activated
factor VII (FVIIa) concentrations after intake of the olive oil,224
and gallic acid and the insulin response and insulin sensitivity
after red grape pomace intake.246
Finally, other studies have not identified the main driver
(or drivers) of beneficial effects despite reporting positive cor-
relations. Thus, Wong et al.239 reported in a postprandial study
that resveratrol intake improved neurovascular coupling
capacity, and the effect was correlated with the total metab-
olites (free form plus conjugates).239 A similar aspect was
found in an acute interventional study in healthy males that
consumed olives, finding a significant correlation between
plasma total phenolics and plasma total antioxidant potential
(TAP) but not with individual phenolic-derived metabolites,
including hydroxytyrosol.225 Besides this, another RCT
reported that equol concentrations were correlated with the
change in carotid-femoral pulse-wave velocity (PWV) after soy
isoflavones intake, but no effect was observed after free equol
intake.150
In contrast, correlations between phenolic-derived metab-
olites and health outcomes are less evident in chronic studies.
This fact is remarkable with the lack of studies that correlated
improvements in FMD and/or blood pressure, even with flava-
nol-derived metabolites such as epicatechin. In this regard,
one RCT conducted in postmenopausal with type 2 diabetes
mellitus patients that consumed flavonoid-enriched chocolate
(27 g d−1) plus 100 mg isoflavones for 1 year reported that
urinary equol concentrations, but not epicatechin and its
metabolites, tended to be inversely correlated with the
reduction in diastolic blood pressure, although only in the
equol producer individuals.251 On the contrary, a certain corre-
lation has been found with other cardiometabolic markers
such as hyperlipidaemia. Thus, urinary anthocyanin metab-
olites such as peonidin-3-O-galactoside, 3-(4-hydroxyphenyl)
propionic acid, and cyanidin-3-O-galactoside were correlated
with lower plasma Tchol and LDLc in a RCT conducted with
49 healthy former smokers after 12-weeks Aronia consump-
tion.241 In the same line, another RCT described that the
plasma oxLDL concentrations were negatively correlated with
the sum of phenolics including hydroxytyrosol and tyrosol
derivatives and the homovanillic acid metabolite in LDL par-
ticles from 36 healthy volunteers that consumed olive oil for 3
weeks.228 However, no correlation was found with antioxidant
markers. Similarly, in another RCT conducted in 100 over-
weight or obese adults that consumed either normal or (poly)
phenol-enriched orange juice for 12 weeks, no correlation was
found with urinary hesperetin and naringenin or their conju-
gated metabolites and several antioxidant markers and
reduction of anthropometric parameters, except for an inverse
correlation with erythrocyte catalase activity.234
Several RCT trials conducted with pomegranate extracts
have tried to correlate different plasma cardiometabolic and
inflammatory risk biomarkers regarding urolithins. However,
most studies did not find correlations between concentration
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changes in urine and plasma of any conjugated urolithin and
the evaluated biomarkers.86,87,139 Besides this, the occurrence
of urolithin levels in human CRC tissues was not correlated
with the modulation of different miRNAs and CRC marker
expression.74,252 González-Sarrías et al.119 reported that total
and single urinary urolithins (Uro-A and B and IsoUro-A) in
subjects that belong to UM-B significantly correlated with a
reduction in LDLc levels, and specifically for Uro-A with total
cholesterol and non-HDLc, after 3-weeks consumption of
pomegranate extract. Besides this, the intake of other ellagitan-
nin-rich sources has yielded contradictory results. In this
regard, Uro-A glucuronide was inversely correlated with basal
abdominal adiposity (WC, waist-hip ratio) and impaired gly-
caemic control (fasting insulin, HOMA-IR) after 12-weeks con-
sumption of mixed nuts (30 g d−1).235 However, no correlation
was found after 1-month strawberry pulp consumption (50 g
d−1) between Uro-A and several antioxidant markers, being the
effects negatively correlated with plasma 4-hydroxyhippuric
acid concentrations.233
Two RCT studies found a correlation between the sum of
circulating curcumin metabolites and the change in Tchol,223
and the increase of intrahepatic lipid content with the
plasma resveratrol levels238 after consuming curcumin and
resveratrol for one month, respectively. On the contrary, in
another RCT conducted in patients with metabolic syndrome
that consumed quercetin for 6 weeks, no correlation was
found between improvements in cardiometabolic and inflam-
matory risk biomarkers with plasma concentrations of
quercetin.250
3. Conclusions and roadmap
A consistent cause-and-effect relationship has been observed
between consuming a few dietary (poly)phenols, including fla-
vanols and phenolics in olive oil, and health effects (endo-
thelial function and prevention of LDL oxidation, respectively).
However, this cause-and-effect relationship has not been well
established for the rest of the dietary phenolics.
To date, the possible final drivers of the effects, at least par-
tially, i.e., the specifically produced metabolite(s) and/or the
gut microbial ecology associated with (poly)phenol metab-
olism (gut microbiota-associated metabotypes), have not been
fully identified. In this regard, several studies have found stat-
istical associations between plasma metabolites and acute
effects such as FMD improvements. This association is likely
to happen if the precursor (pure (poly)phenol or phenolic-con-
taining food) exerts an effect. In this case, as it is logical to
observe the concomitant increase in plasma of the derived
phenolic metabolites, the statistical possibility of finding a cor-
relation between effect and metabolite concentration will be
high. Likewise, a non-targeted plasma analysis could also yield
many possible associations between FMD (or other acute deter-
minations) and the concomitant presence of other plasma
metabolites during the assay (e.g., vitamins, amino acids, and
many others).
However, these associations are usually lost in longer
studies due to the high turnover of phenolic metabolites.
Besides this, significant statistical associations do not necess-
arily involve causality or clinical relevance.
Cross-sectional associations to observe differential health
effects depending on the gut microbial ecology are insufficient
to prove both causality and temporality in the effects. Due to
the vast amount of interfering variables that affect the individ-
uals’ response to (poly)phenol consumption, randomised and
placebo-control trials are mandatory to establish a causal role
between specific gut microbial ecologies (gut microbiota meta-
botypes) and health effects. In this regard, several points like
clustering subjects according to their gut microbiota-associ-
ated metabotypes, production of metabolite level, age (since
metabotypes might change with age) or phase-II polymorph-
isms, as well as qualitative and quantitative assessments of the
circulating (and excreted) metabolites to find strong corre-
lations should be considered in further RCT studies. No single
associations are sufficient to prove causality (even from a
RCT). Therefore, RCTs should include a crossover and dose–
response design as a first step in demonstrating causality vs.
apparent statistical associations of circulating metabolites and
effects.
The genetic makeup can contribute to defining the impact
of dietary (poly)phenols on human health. Therefore, there is
a need for investigating the role of polymorphisms of transpor-
ters and enzymes involved in the ADME of (poly)phenols. The
contribution of these polymorphisms on the existence of
specific polyphenol-related metabotypes is uncertain.
However, they could modulate the bioavailability of dietary
(poly)phenols critically and consequently affect the health
effects.
Instead of animal to human, we should perform human to
animal translational approaches to prove in animals the causal
role of specific phenolic-derived metabolites produced by
humans and/or their gut microbiota metabotypes. For
example, after consuming dietary (poly)phenols, the human
plasmatic phenolic signature should be administered (intra-
venously or intraperitoneally) to animal models to check a sys-
temic cause-and-effect relationship. Similarly, the qualitative
and quantitative profile of phenolic-derived metabolites found
in human tumours after consuming dietary (poly)phenols
could be injected chronically into tumours of xenograft animal
models to verify their specific response to the challenge of phe-
nolic-derived metabolites individually or as a mix.
In the same line, specific gut microbes, a consortium of
microbes or faecal transplants characteristic of specific human
gut microbiota metabotypes, should be assayed in animal
models to demonstrate their causal role in health effects.
Identifying the actual metabolites ultimately responsible
for the health effects after (poly)phenol consumption remains
elusive. Nevertheless, we believe that the approaches given
above, in combination with growing evidence for the biological
effects of circulating metabolites, thanks to physiologically
relevant mechanistic studies using circulating phenolic-
derived metabolites, but not the forms present in foods, will
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contribute to identifying the putative drivers responsible for
the health effects attributed to (poly)phenols.
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